KPV vs BPC-157: how they compare for gut health and inflammation

People searching for KPV vs BPC-157 are usually interested in the gut: inflammatory bowel disease, colitis, leaky gut or general digestive symptoms. Both peptides are sold for that purpose, and both are sometimes sold together. The research behind them is quite different, though. KPV is essentially an anti-inflammatory molecule studied in cells and mice. BPC-157 is a repair-focused peptide studied mostly in rats, with gut protection as its original research area.

Neither peptide has a published controlled trial in people with a gut condition. Every gut result on this page comes from cell or animal experiments, and neither peptide is an approved medicine. For background on how such products are sold, see what research peptides are.

KPV is a tripeptide of lysine, proline and valine. It matches positions 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid hormone involved in skin pigmentation and inflammation ^[1]. It has been studied as a small fragment that keeps some of alpha-MSH's anti-inflammatory activity ^{[1] [2]}. It should not be confused with melanotan II, a larger synthetic alpha-MSH analogue designed to act on melanocortin receptors.

BPC-157 is a pentadecapeptide with the sequence GEPPPGKPADDAGLV. It was developed by a group at the University of Zagreb from a protein they described in gastric juice, and that group has produced most of the research since ^{[8] [13]}. In the 2000s it was described as being in clinical trials for inflammatory bowel disease under the code PL 14736 ^[8]. We found no peer-reviewed results from those trials.

KPV appears to act inside cells. In a 2008 study, it was carried into human intestinal cells and T cells by PepT1, a transporter for small peptides that increases in the colon during inflammatory bowel disease. At nanomolar concentrations it reduced activation of the NF-κB and MAP kinase inflammatory pathways and lowered inflammatory cytokine release ^[3]. Whether KPV also works through melanocortin receptors is disputed. A 2003 study concluded it was unlikely to, and pointed to inhibition of interleukin-1β instead ^[2]. Another 2003 paper reported that KPV could bind the melanocortin-1 receptor ^[15]. In mice lacking a working melanocortin-1 receptor, KPV still protected against colitis, suggesting its effects are at least partly independent of that receptor ^[4].

BPC-157 is linked mainly to blood-vessel growth and tissue repair. In laboratory work it increased the expression and activation of VEGFR2, a receptor for the growth factor VEGF, and switched on the Akt–eNOS pathway that produces nitric oxide ^[10]. Reviews from its originating group also describe interactions with the nitric oxide system and protection of the lining of blood vessels ^{[7] [8]}. No single receptor for BPC-157 has been identified.

Put simply, KPV is studied as a way to quieten inflammation, and BPC-157 as a way to speed repair. That is why sellers pair them. It is a rationale, not a result: no study has tested the two together.

KPV's gut evidence comes from mouse colitis models. In the 2008 PepT1 study, KPV given in drinking water reduced the incidence of colitis induced by the chemicals DSS and TNBS, with lower inflammatory cytokine levels ^[3]. A second 2008 study, from Münster, found that KPV sped recovery and weight regain in DSS colitis, reduced inflammatory cell infiltrates and the inflammation marker myeloperoxidase, and helped mice recover in a T-cell transfer colitis model ^[4].

Later work has focused on getting KPV to the colon. In a 2017 study, KPV loaded into hyaluronic-acid-coated nanoparticles and given by mouth in a hydrogel reduced mucosal damage and the inflammatory signal TNF-α in mice with ulcerative colitis ^[6]. These are formulation experiments. They do not show what a KPV capsule or injection sold online would do in a person.

BPC-157 was first studied as a stomach-protective agent, and gut research remains a large part of its literature. A 2011 review from the Zagreb group described effects in rat models of lesions of the oesophagus, stomach, duodenum, intestine, liver and pancreas, and reported healing of intestinal anastomoses and several types of fistula in rats ^[7]. In a 2013 study from the same group, BPC-157 healed cysteamine-induced colitis and colon-to-colon anastomoses in rats, given either by injection at 10 µg/kg or 10 ng/kg, or in drinking water ^[9].

Almost all of this work comes from one laboratory, and a 2025 systematic review graded the wider BPC-157 evidence base as level IV and V, with no clinical safety data ^[13]. The reviews describe the inflammatory bowel disease trials as "safe" ^{[7] [8]}, but we could not find their results published for independent review. Claims that BPC-157 treats colitis or leaky gut in people are not supported by published trials.

For KPV there is none. The FDA has said it "has not identified any human exposure data" on products containing KPV by any route ^[5].

For BPC-157 there are three small pilot reports from private US clinics: knee injections in 16 people, bladder-wall injections in 12 women with interstitial cystitis, and intravenous infusion in two healthy adults ^[11]. None looked at gut disease, none had a placebo group, and together they involved about 30 people. On human evidence, then, BPC-157 has a little and KPV has none, and for the gut neither has any.

Both peptides are sold as capsules as well as injectable powders, and oral use makes some sense for a gut target. In mice, KPV was active when given in drinking water ^[3] and in oral nanoparticle formulations designed to reach the colon ^[6]. In rats, BPC-157 was active in drinking water in gut models ^[9], and its developers describe it as stable in human gastric juice ^[8].

What is missing is any human data on oral absorption or effect for either peptide. Pharmacokinetic work on BPC-157 in rats and dogs used injections and found a half-life under 30 minutes, with the peptide broken down into small fragments and amino acids ^[12]. We found no pharmacokinetic study of KPV. Animal results with purpose-made formulations do not tell you how a retail capsule behaves.

We found no study of KPV and BPC-157 together, in cells, animals or people. Suppliers do sell them in combination. Examples include multi-peptide bundles aimed at inflammation, and the four-peptide Klow blend, which sellers describe as KPV with BPC-157, TB-500 and GHK-Cu. The closest tested combination involving BPC-157 is a 2026 rat study that paired it with TB-500 for tendon repair and found no added benefit ^[16]. That result says nothing about KPV.

Because there is no research on the pair, there is no evidence-based ratio, dose or schedule for BPC-157 and KPV. Anything presented as a protocol for the combination is not drawn from published data.

KPV: cell studies used nanomolar concentrations, and mouse studies gave it in drinking water or in oral nanoparticles ^{[3] [6]}. The abstracts do not give a human-equivalent amount, and no human dose exists.

BPC-157: in the 2013 rat gut study it was injected into the abdomen at 10 µg/kg or 10 ng/kg once daily, or given in drinking water ^[9]. In the human pilot reports, the interstitial cystitis study used 10 mg injected into the bladder wall once, and the intravenous safety study gave 10 mg and then 20 mg on consecutive days ^[11]. These figures describe what studies used. They are not recommendations, and animal doses should not be converted to human doses.

For converting the milligrams in a vial to a concentration after mixing, the peptide calculator does the arithmetic, and our bacteriostatic water guide explains the diluent. Neither indicates an appropriate amount.

KPV has no human safety data. The FDA said it "lacks important information regarding any safety issues raised by KPV" ^[5]. The 2017 nanoparticle study reported that its KPV particles appeared non-toxic to intestinal cells ^[6], but that does not establish safety in people.

BPC-157's three pilot reports described no adverse events, but they were tiny and short ^[11]. The FDA has said compounded BPC-157 may pose a risk of immune reactions for some routes of administration and raises questions about peptide-related impurities ^[5]. Because BPC-157 promotes blood-vessel growth in laboratory models ^[10], some reviewers have raised the untested question of whether it could affect existing tumours.

Side effects of KPV and BPC-157 taken together have never been studied. Product quality adds risk to both, since research peptides are not made to medicine standards. Checking a certificate of analysis and using third-party tested suppliers reduces, but does not remove, that risk.

Neither peptide is approved as a medicine. In the US, the FDA previously placed both in category 2 of its compounding policy, the list of bulk substances that may present significant safety risks. The nominations were later withdrawn, and the FDA now lists both among substances previously in category 2 ^[5]. Its Pharmacy Compounding Advisory Committee considered both on 23 July 2026. The FDA's meeting page had posted no outcome when we checked, and the FDA has not acted ^[17].

Health Canada's April 2026 advisory named both BPC-157 and KPV among seized unauthorised peptides ^[18]. For national rules, see our legal status overview and the US legal status page.

For athletes, BPC-157 is named on the WADA Prohibited List under S0 and is prohibited at all times ^[14]. KPV is not named in the 2026 List text we checked, and we have not confirmed its status.

We track KPV suppliers in the UK and other markets, as well as BPC-157 in the UK. Capsules, injectable powders and blends are priced differently, so compare the price per milligram of each peptide. Our guide to storing peptides covers how powders and mixed solutions are usually kept.